Case Study

Leading CRO Accelerates Startup with Integrated, Centralized IRB/IBC Reviews 

Understanding the nuances of mRNA study timelines and regulatory requirements are particularly important given market pressures and patient need.

Knowing this, Parexel engaged Advarra to help rapidly launch studies with genetically engineered therapeutics and vaccines.

Advarra’s integrated central IRB and IBC review services helped Parexel accelerate the delivery of life-saving and innovative gene therapies.

The CRO delivered first patient/first visit on time and on budget with Advarra’s site reviews:
  • IBC review: 1.8 business days average
  • IRB review: 1.7 business days average

Download the case study.

Who Should Watch?

CEU Credits

Certificate of Attendance

Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Download Now